12 week phase 2 study of QR-010 in Cystic Fibrosis patients with the F508del mutation.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Eluforsen (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 07 Mar 2018 New trial record
- 28 Feb 2018 According to a ProQR Therapeutics media release, this trial is expected to start in 2018.